Prognostic value of chromosomal abnormalities (univariate analysis)
| Genomic aberration . | Impact on EFS, mo*(P) . | Impact on OS†(P) . |
|---|---|---|
| del(13) | 29 vs 41 (< .001) | 68% vs 83% (< .001) |
| t(11;14)(q13;q32) | 35 vs 34 (.2) | 80% vs 74% (.28) |
| t(4;14)(p16;q32) | 20.6 vs 36.5 (< .001) | 41.3 months vs 79% (< .001) |
| Hyperdiploidy | 37 vs 33 (.02) | 82% vs 70% (.006) |
| MYC translocations | 35 vs 37 (.94) | 72% vs 78% (.50) |
| del(17p) | 15 vs 35 (< .001) | 22 months vs 75% (< .001) |
| Genomic aberration . | Impact on EFS, mo*(P) . | Impact on OS†(P) . |
|---|---|---|
| del(13) | 29 vs 41 (< .001) | 68% vs 83% (< .001) |
| t(11;14)(q13;q32) | 35 vs 34 (.2) | 80% vs 74% (.28) |
| t(4;14)(p16;q32) | 20.6 vs 36.5 (< .001) | 41.3 months vs 79% (< .001) |
| Hyperdiploidy | 37 vs 33 (.02) | 82% vs 70% (.006) |
| MYC translocations | 35 vs 37 (.94) | 72% vs 78% (.50) |
| del(17p) | 15 vs 35 (< .001) | 22 months vs 75% (< .001) |
Median EFS for patients presenting the chromosomal abnormality versus that of those who did not present the genomic aberration.
Median OS for patients presenting the chromosomal abnormality versus that of those who did not present the genomic aberration. When the median was not attained, we did calculate the percentage of patients alive at the time of median follow-up (ie, 41 months).